## CRL: Charles River Laboratories International, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.0% below STRENGTH zone (3.0-6.0%); RSI 70 overbought. Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.3% MRS), overbought RSI (70).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($192.85)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Rating of "Moderate Buy" from Analysts**
- Source: MarketBeat | 20251229T064315 | Somewhat-Bullish | Relevance: 100%
- Charles River Laboratories International, Inc. (NYSE:CRL) has received an average rating of "Moderate Buy" from eighteen analyst firms, with a consensus 12-month average target price of $195.93. Several analysts recently adjusted their price targets, indicating continued interest in the stock. Despite trading near its 52-week high and institutional ownership of nearly 99%, the company reported a negative P/E ratio and net margin, reflecting recent margin pressures.

**2. Charles River Laboratories International, Inc. $CRL Stake Cut by Norris Perne & French LLP MI**
- Source: MarketBeat | 20251229T122958 | Somewhat-Bullish | Relevance: 100%
- Norris Perne & French LLP MI significantly reduced its stake in Charles River Laboratories International (NYSE:CRL) by 92% in Q3, selling over 110,000 shares. Despite this, other institutional investors have recently increased their positions, and Charles River Laboratories reported strong Q3 earnings, beating analyst estimates with $2.43 EPS and $1 billion in revenue. The company maintains a "Moderate Buy" analyst consensus with a target price around $195.93.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $200 | $174 | +15% |
| 2025-12-15 | Barclays | $215 | $210 | +2% |
| 2025-12-15 | JP Morgan | $190 | $165 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Neutral |
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.15 indicates undervaluation relative to growth. Forward P/E 18.6x stretched relative to 7% growth. Analyst sentiment positive (3 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $10.0B |
| Beta | 1.64 |
| 52W Range | $91.86 - $205.00 |
| Short Interest | 5.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.15 |
| Forward P/E | 18.6 |
| Current P/E | 19.8 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.3% to 1.0% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.0pp (needs >3.0% for momentum thesis). MRS_5 at 0.3% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.69), confirming momentum. RSI overbought at 70, risk of mean reversion. OFD pattern: +DUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.97% (CS: 86) | Neutral |
| RSI_14 | 70.4 | Overbought |
| MACD Histogram | 0.69 | Bullish |
| vs SMA20 | 1.054x | Above |
| vs SMA50 | 1.111x | Above |
| vs SMA200 | 1.285x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $203.19
- **Stop Loss:** $192.85 (5.1% risk)
- **Target:** $213.53 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 133
- **Position Value:** $27,024.27
- **Portfolio %:** 27.02%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*